In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population
Authors:
- Yu-Han WangYWYu-Han Wang
- Shuang-Hu WangSWShuang-Hu Wang
- Pei-Wu GengPGPei-Wu Geng
- Li-Ming HuLHLi-Ming Hu
- Guo-Xin HuGHGuo-Xin Hu
- Jian-Ping CaiJCJian-Ping Cai
- 30 September 2013
- journal article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 34 (11) , 1449-1456
Abstract
Cytochrome P450 2C9 (CYP2C9) is a polymorphic enzyme that is responsible for the metabolism of approximately 15% of clinically important drugs. The aim of this study was to assess the catalytic characteristics of 37 CYP2C9 allelic isoforms found in Chinese Han population on the metabolism of tolbutamide in vitro. The wild-type and 36 CYP2C9 variants were expressed in sf21 insect cells using a baculovirus-mediated expression system. Then the insect microsomes were prepared for assessing the metabolic characteristics of each variant toward the CYP2C9-specific drug substrate tolbutamide. Of 36 allelic variants tested, the intrinsic clearance values of 2 allelic isoforms (CYP2C9.36 and CYP2C9.51) were much higher than the wild-type CYP2C9.1 protein, 3 allelic isoforms (CYP2C9.11, CYP2C9.56 and N418T) exhibited similar intrinsic clearance values as the wild-type enzyme, whereas the other 31 variants showed significantly reduced intrinsic clearance values, ranging from 0.08% to 66.88%, for tolbutamide. Our study provides the most comprehensive data concerning the enzymatic activity of the CYP2C9 variants that are present in the Chinese Han population, and our data suggest that most of the carriers of these alleles might be paid more attention when using CYP2C9 mediated drugs clinically.Keywords
This publication has 27 references indexed in Scilit:
- CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency databaseThe Pharmacogenomics Journal, 2013
- Allele and genotype frequencies of CYP2C9 in a Korean populationBritish Journal of Clinical Pharmacology, 2005
- haplotype structure in European American warfarin patients and association with clinical outcomesClinical Pharmacology & Therapeutics, 2005
- Novel genetic variants in Asian subjects and their influence on maintenance warfarin doseClinical Pharmacology & Therapeutics, 2004
- Discovery of new potentially defective alleles of human CYP2C9Pharmacogenetics, 2004
- Identification of a novel variant CYP2C9 allele in ChinesePharmacogenetics, 2004
- No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3European Journal of Clinical Pharmacology, 2003
- Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locusPharmacogenetics, 2000
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994